Drug intelligence / Profile preview

mimopezil

Development stage: Phase 2
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral, Subcutaneous Implant

Overview

Mimopezil is an experimental small molecule acetylcholinesterase (AChE) inhibitor developed as a pro-drug for the treatment of Alzheimer's disease. After administration, mimopezil is rapidly absorbed and converted into huperzine A, its active metabolite. Huperzine A inhibits acetylcholinesterase, thereby increasing levels of acetylcholine in the brain and potentially improving cognitive function in Alzheimer's disease patients. The drug was initially developed by the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and later advanced by Debiopharm International SA[1][3][8].

Other names: MimopezilMimopézilMimopeziloMimopezilumN-(2-Hydroxy-3-methoxy-5-chlorobenzylidene)huperzine A

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on mimopezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mimopezil.

Explore the full profile